(American Journal of Health System Pharmacy[TA])
12,193 results
  • Practice-enhancing publications about the medication-use process in 2025. [Journal Article]
    Am J Health Syst Pharm. 2026 Jul 14. [Online ahead of print]Vest TA, O'Neil DP, … Eckel SFAJ
  • CONCLUSIONS: It is important to routinely review the published literature and to incorporate significant findings into daily practice. This article assists in identifying and summarizing those most impactful. Health-system pharmacists have an active role in improving the MUP in their institution, and awareness of the significant published studies can assist in changing practice at the institutional level.
  • Publisher Full Text (DOI)
  • Abnormal dreams and night terrors with atogepant: A case series. [Journal Article]
    Am J Health Syst Pharm. 2026 Jul 13. [Online ahead of print]To J, Cournoyer H, … MacDougall JAJ
  • CONCLUSIONS: Abnormal dreams and night terrors may represent an underrecognized adverse effect of atogepant. Based on this case series, the effect appears potentially reversible with discontinuation and may diminish over time in some patients who continue therapy. For patients who are taking atogepant and report sleep disturbances and dream-related symptoms, a possible correlation with atogepant should be considered. During follow-up, proactively asking about sleep disturbances and dream-related symptoms should be considered.
  • Publisher Full Text (DOI)
  • Clinical controversies in the management of candidemia in adults and children. [Journal Article]
    Am J Health Syst Pharm. 2026 Jul 11. [Online ahead of print]Cluck DB, White BP, … Chastain DBAJ
  • CONCLUSIONS: Optimal candidemia management increasingly depends on individualized antifungal strategies, integration of RDTs and AFST, earlier species-directed therapy transitions, and selective evaluation for metastatic complications. Future studies are needed to better define uncomplicated candidemia, optimize treatment duration, and address evolving antifungal resistance.
  • Publisher Full Text (DOI)
  • Optimizing transitions from direct factor Xa inhibitors to unfractionated heparin therapy. [Journal Article]
    Am J Health Syst Pharm. 2026 Jul 04. [Online ahead of print]Gulseth MP, Dinunno C, … Smythe MAAJ
  • CONCLUSIONS: Each hospital or health system should develop a structured approach for managing DFXaI to UFH transitions. Ideally, the transition should be managed by pharmacists and involve measurement of residual DFXaI anticoagulation to inform the timing of UFH initiation. Prospective studies are needed to better define best practices.
  • Publisher Full Text (DOI)
  • Impact of pharmacist involvement on hospital sepsis response teams. [Journal Article]
    Am J Health Syst Pharm. 2026 Jul 04. [Online ahead of print]Vanini D, Reid S, … Groth CMAJ
  • CONCLUSIONS: Pharmacist involvement in a sepsis response team is associated with improved completion of the 1-hour bundle, specifically the early administration of broad-spectrum antibiotics. Early identification of sepsis and alerting a multidisciplinary team remain barriers to optimizing treatment.
  • Publisher Full Text (DOI)
  • Zoliflodacin: A novel single-dose oral antibiotic for uncomplicated urogenital gonorrhea. [Journal Article]
    Am J Health Syst Pharm. 2026 Jul 03. [Online ahead of print]Durham SH, Chahine EBAJ
  • CONCLUSIONS: Zoliflodacin is a newly approved antibiotic with a novel mechanism of action that is highly effective for the treatment of uUGG. It is given as a single dose that can be administered orally at the time of diagnosis, thereby avoiding the intramuscular injection necessary with ceftriaxone. It is also effective against gonorrhea strains resistant to other antibiotics.
  • Publisher Full Text (DOI)